Tesaglitazar

Tesaglitazar is a dual-target PPARα/γ agonist with an EC50 of 13.4 μM for rat PPARα and 3.6 μM for human PPARα. Tesaglitazar affects lipid and glucose metabolism by activating PPARα and PPARγ receptors, and has the potential to improve blood sugar and relieve pain. Tesaglitazar can be used to induce in vivo tumor models and can be used in the study of type 2 diabetes, dyslipidemia, and neuropathic pain[1][2][3].

Product Specifications

CAS Number

[251565-85-2]

UNSPSC

12352005

Hazard Statement

H302

Target

PPAR

Type

Reference compound

Related Pathways

Cell Cycle/DNA Damage; Metabolic Enzyme/Protease; Vitamin D Related/Nuclear Receptor

Applications

Neuroscience-Neuromodulation

Field of Research

Cancer; Metabolic Disease

Assay Protocol

https://www.medchemexpress.com/tesaglitazar.html

Purity

99.08

Solubility

DMSO : 200 mg/mL (ultrasonic; warming; heat to 60°C)

Smiles

O=C(O)[C@@H](OCC)CC1=CC=C(OCCC2=CC=C(OS(=O)(C)=O)C=C2)C=C1

Molecular Formula

C20H24O7S

Molecular Weight

408.47

Precautions

H302

References & Citations

[1]Hellmold H, et al. Tesaglitazar, a PPARalpha/gamma agonist, induces interstitial mesenchymal cell DNA synthesis and fibrosarcomas in subcutaneous tissues in rats. Toxicol Sci. 2007 Jul;98 (1) :63-74.|[2]Quarta C, et al. GLP-1-mediated delivery of tesaglitazar improves obesity and glucose metabolism in male mice. Nat Metab. 2022 Aug;4 (8) :1071-1083.|[3]Alsalem M, et al. Effects of Dual Peroxisome Proliferator-Activated Receptors α and γ Activation in Two Rat Models of Neuropathic Pain. PPAR Res. 2019 Apr 17;2019:2630232.